[-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer from Benign Disease in a Prospective Prostate Cancer Screening Study

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2010 Feb 23

PMID 20171670

Citations 52

Authors

Brian V Le

Christopher R Griffin

Stacy Loeb

Gustavo F Carvalhal

Donghui Kan

Nikola A Baumann

William J Catalona

Affiliations

Soon will be listed here.

Abstract

Purpose: Due to the limited specificity of prostate specific antigen for prostate cancer screening, there is an ongoing search for adjunctive biomarkers. Retrospective studies have suggested that an isoform of proenzyme prostate specific antigen called [-2]proenzyme prostate specific antigen may enhance the specificity of prostate specific antigen based screening. We examined the usefulness of this isoform in a prospective prostate cancer screening study.

Materials And Methods: From a population of 2,034 men undergoing prostate cancer screening we examined the relationship between the measurement of the [-2]isoform of proenzyme prostate specific antigen (p2PSA) and prostate cancer detection. Specifically we compared the usefulness of total prostate specific antigen, the ratio of free-to-total prostate specific antigen, the ratio of p2PSA-to-free prostate specific antigen, and a formula combining prostate specific antigen, free prostate specific antigen and p2PSA (the Beckman Coulter prostate health index or phi) to predict prostate cancer in men from the study undergoing prostate biopsy with a prostate specific antigen of 2.5 to 10 ng/ml and nonsuspicious digital rectal examination.

Results: Despite similar total prostate specific antigen (p = 0.88), percent free prostate specific antigen (p = 0.02) and %p2PSA (p = 0.0006) distinguished between positive and negative biopsy results. On ROC analysis %p2PSA (AUC 0.76) outperformed prostate specific antigen (AUC 0.50) and percent free prostate specific antigen (AUC 0.68) for differentiating between prostate cancer and benign disease. Setting the sensitivity at 88.5%, p2PSA led to a substantial improvement in specificity as well as positive and negative predictive values. The Beckman Coulter prostate health index (AUC 0.77) had the best overall performance characteristics.

Conclusions: This is the first prospective study to our knowledge to demonstrate that p2PSA provides improved discrimination between prostate cancer and benign disease in screened men with a prostate specific antigen of 2.5 to 10 ng/ml and a negative digital rectal examination.

Citing Articles

Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.

Bratt O, Auvinen A, Arnsrud Godtman R, Hellstrom M, Hugosson J, Lilja H BMJ Oncol. 2025; 2(1):e000039.

PMID: 39886507 PMC: 11203092. DOI: 10.1136/bmjonc-2023-000039.

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

Associations of HALP score with serum prostate-specific antigen and mortality in middle-aged and elderly individuals without prostate cancer.

Chen Z, Zhang Y, Dan M, Hong X, Chen S, Zhong X Front Oncol. 2024; 14:1419310.

PMID: 39372874 PMC: 11449680. DOI: 10.3389/fonc.2024.1419310.

Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer.

Qian Y, Shi Y, Sheng X, Liao H, Chen H, Shi B Clin Med Insights Oncol. 2023; 17:11795549231201122.

PMID: 37869472 PMC: 10588416. DOI: 10.1177/11795549231201122.

Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways.

Lophatananon A, Light A, Burns-Cox N, Maccormick A, John J, Otti V J Clin Urol. 2023; 16(4):264-273.

PMID: 37614642 PMC: 7614972. DOI: 10.1177/20514158211059057.

References

de Vries S, Raaijmakers R, Blijenberg B, Mikolajczyk S, Rittenhouse H, Schroder F . Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology. 2005; 65(5):926-30. DOI: 10.1016/j.urology.2004.11.030. View

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Horninger W . Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004; 171(6 Pt 1):2239-44. DOI: 10.1097/01.ju.0000127737.94221.3e. View

Mikolajczyk S, Millar L, Wang T, Rittenhouse H, Marks L, Song W . A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000; 60(3):756-9. View

Lilja H . Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am. 1993; 20(4):681-6. View

Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Amirkhan A . Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003; 170(6 Pt 1):2181-5. DOI: 10.1097/01.ju.0000095460.12999.43. View

Roehl K, Antenor J, Catalona W . Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol. 2002; 168(3):922-5. DOI: 10.1016/S0022-5347(05)64543-0. View

Mikolajczyk S, Catalona W, Evans C, Linton H, Millar L, Marker K . Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004; 50(6):1017-25. DOI: 10.1373/clinchem.2003.026823. View

10.

Mikolajczyk S, Marks L, Partin A, Rittenhouse H . Free prostate-specific antigen in serum is becoming more complex. Urology. 2002; 59(6):797-802. DOI: 10.1016/s0090-4295(01)01605-3. View

11.

Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, depaula F, Pansadoro V . The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001; 166(3):845-50. View

12.

Woodrum D, Brawer M, Partin A, Catalona W, Southwick P . Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1997; 159(1):5-12. DOI: 10.1016/s0022-5347(01)63996-x. View

13.

Sokoll L, Wang Y, Feng Z, Kagan J, Partin A, Sanda M . [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008; 180(2):539-43. PMC: 2647141. DOI: 10.1016/j.juro.2008.04.015. View

14.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

15.

Okihara K, Fritsche H, Ayala A, Johnston D, Allard W, Babaian R . Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol. 2001; 165(6 Pt 1):1930-6. DOI: 10.1097/00005392-200106000-00021. View

16.

Sokoll L, Chan D, Mikolajczyk S, Rittenhouse H, Evans C, Linton H . Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology. 2003; 61(2):274-6. DOI: 10.1016/s0090-4295(02)02398-1. View

17.

Mikolajczyk S, Grauer L, Millar L, Hill T, Kumar A, Rittenhouse H . A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 1997; 50(5):710-4. DOI: 10.1016/S0090-4295(97)00449-4. View

18.

Pinsky P, Andriole G, Kramer B, Hayes R, Prorok P, Gohagan J . Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2005; 173(3):746-50. DOI: 10.1097/01.ju.0000152697.25708.71. View

19.

Naya Y, Fritsche H, Bhadkamkar V, Mikolajczyk S, Rittenhouse H, Babaian R . Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol. 2005; 23(1):16-21. DOI: 10.1016/j.urolonc.2004.07.017. View

20.

Chan T, Mikolajczyk S, Lecksell K, Shue M, Rittenhouse H, Partin A . Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology. 2003; 62(1):177-81. DOI: 10.1016/s0090-4295(03)00138-9. View